Natera designed a prospective study named EDEN to evaluate risk during early pregnancy using non-invasive prenatal screening tests across the world. The EDEN study is focused on identifying preeclampsia and other adverse pregnancy outcomes early in gestation. Preeclampsia occurs in five to eight percent of worldwide pregnancies and is one of the main reasons for complications. Adverse pregnancy outcomes affect about one in five pregnancies in the United States.
Study Design and Scope
The EDEN study combines cell-free DNA analysis, clinical data, and additional analytes into a comprehensive risk assessment approach.
Up to seven thousand five hundred pregnant participants will be enrolled from nine to fifteen weeks of gestation. Researchers will evaluate risk for early-onset, severe preeclampsia as well as other major complications of pregnancy. Previous studies associated certain cfDNA markers with a higher risk of adverse pregnancy outcomes. Previous studies indicated that cfDNA, combined with patient characteristics, was able to predict the risk for preeclampsia without specialized imaging technologies.
Executive Perspective
“For more than a decade, Natera has advanced pregnancy care through highly sensitive non-invasive testing,” said Sheetal Parmar, senior vice president of medical affairs at Natera. “With EDEN, we are assessing a next-generation test, which can detect pregnancies that are at higher risk sooner and more precisely.” This study justifies proactive maternal care decisions worldwide and attempts to optimize pregnancy outcomes through earlier clinical interventions. Authors’ expectations: The study results will be applicable in future prenatal tests.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
